"58" . . . . . . . "8"^^ . . "Langerhans cell histiocytosis; lenalidomide; 2-chlorodeoxyadenosine; etoposide"@en . "10"^^ . "Adam, Zden\u011Bk" . "Lenalidomid indukoval l\u00E9\u010Debnou odpov\u011B\u010F u pacienta s agresivn\u00ED multisyst\u00E9movou formou histiocyt\u00F3zy z Langerhansov\u00FDch bun\u011Bk (LCH), rezistentn\u00ED ke 2-chlorodeoxyadenosinu a \u010Dasn\u011B relabuj\u00EDc\u00ED po vysokod\u00E1vkovan\u00E9 chemoterapii ..."@cs . "P(LC06027), P(NT11154), Z(MSM0021622434)" . "14"^^ . . . "Histiocyt\u00F3za z Langerhansov\u00FDch bun\u011Bk (LCH) u dosp\u011Bl\u00FDch je ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F p\u0159\u00EDzniv\u011B prob\u00EDhaj\u00EDc\u00ED nemoc. Zcela ojedin\u011Ble se v\u0161ak vyskytne LCH s multisyst\u00E9mov\u00FDm (multiorg\u00E1nov\u00FDm) posti\u017Een\u00EDm, kter\u00E1 nereaguje na klasickou l\u00E9\u010Dbu prvn\u00ED linie (vinblastin, merkaptopurin, prednison anebo etoposid) ani na l\u00E9\u010Dbu 2-chlorodeoxyadenosinem. U t\u011Bchto pacient\u016F je nutn\u00E9 testovat jin\u00E9 l\u00E9\u010Debn\u00E9 alternativy. Popisujeme pacienta s LCH, kter\u00E1 zp\u016Fsobila generalizovanou lymfadenopatii, infiltrovala plicn\u00ED parenchym a k\u016F\u017Ei. Aktivitu nemoci v\u017Edy prov\u00E1zely B symptomy (\u00FAbytek hmotnosti, subfebrilie a febrilie, no\u010Dn\u00ED pocen\u00ED). Histologick\u00E9 vy\u0161et\u0159en\u00ED opakovan\u011B prok\u00E1zalo vy\u0161\u0161\u00ED prolifera\u010Dn\u00ED aktivitu, ne\u017E je obvykl\u00E1 u dosp\u011Bl\u00FDch pacient\u016F s LCH. Exprese prolifera\u010Dn\u00EDho markeru Ki-67 dosahovala a\u017E 30 % a v zorn\u00E9m poli mikroskopu bylo 8\u201310 mit\u00F3z. Proto byla l\u00E9\u010Dba zah\u00E1jena sb\u011Brem kmenov\u00FDch krvetvorn\u00FDch bun\u011Bk z perifern\u00ED krve po aplikaci stimula\u010Dn\u00EDho re\u017Eimu (cyklofosfamid 2 g/m2 den 1 a etoposidu 200 mg/m2 den 1\u20133)." . "14110" . . "RIV/00216224:14110/12:00059513" . "0042-773X" . . . . "Pour, Lud\u011Bk" . "Mayer, Ji\u0159\u00ED" . . . . "Histiocyt\u00F3za z Langerhansov\u00FDch bun\u011Bk (LCH) u dosp\u011Bl\u00FDch je ve v\u011Bt\u0161in\u011B p\u0159\u00EDpad\u016F p\u0159\u00EDzniv\u011B prob\u00EDhaj\u00EDc\u00ED nemoc. Zcela ojedin\u011Ble se v\u0161ak vyskytne LCH s multisyst\u00E9mov\u00FDm (multiorg\u00E1nov\u00FDm) posti\u017Een\u00EDm, kter\u00E1 nereaguje na klasickou l\u00E9\u010Dbu prvn\u00ED linie (vinblastin, merkaptopurin, prednison anebo etoposid) ani na l\u00E9\u010Dbu 2-chlorodeoxyadenosinem. U t\u011Bchto pacient\u016F je nutn\u00E9 testovat jin\u00E9 l\u00E9\u010Debn\u00E9 alternativy. Popisujeme pacienta s LCH, kter\u00E1 zp\u016Fsobila generalizovanou lymfadenopatii, infiltrovala plicn\u00ED parenchym a k\u016F\u017Ei. Aktivitu nemoci v\u017Edy prov\u00E1zely B symptomy (\u00FAbytek hmotnosti, subfebrilie a febrilie, no\u010Dn\u00ED pocen\u00ED). Histologick\u00E9 vy\u0161et\u0159en\u00ED opakovan\u011B prok\u00E1zalo vy\u0161\u0161\u00ED prolifera\u010Dn\u00ED aktivitu, ne\u017E je obvykl\u00E1 u dosp\u011Bl\u00FDch pacient\u016F s LCH. Exprese prolifera\u010Dn\u00EDho markeru Ki-67 dosahovala a\u017E 30 % a v zorn\u00E9m poli mikroskopu bylo 8\u201310 mit\u00F3z. Proto byla l\u00E9\u010Dba zah\u00E1jena sb\u011Brem kmenov\u00FDch krvetvorn\u00FDch bun\u011Bk z perifern\u00ED krve po aplikaci stimula\u010Dn\u00EDho re\u017Eimu (cyklofosfamid 2 g/m2 den 1 a etoposidu 200 mg/m2 den 1\u20133)."@cs . . "Lenalidomid induced therapeutic response in a patient with agressive multisystemic Langerhans cell histiocytosis, resistant to 2-chlorodeoxyadenosine and early relapsing after high dose chemotherapy ..."@en . . . "Lenalidomid indukoval l\u00E9\u010Debnou odpov\u011B\u010F u pacienta s agresivn\u00ED multisyst\u00E9movou formou histiocyt\u00F3zy z Langerhansov\u00FDch bun\u011Bk (LCH), rezistentn\u00ED ke 2-chlorodeoxyadenosinu a \u010Dasn\u011B relabuj\u00EDc\u00ED po vysokod\u00E1vkovan\u00E9 chemoterapii ..."@cs . "1" . . "Lenalidomid indukoval l\u00E9\u010Debnou odpov\u011B\u010F u pacienta s agresivn\u00ED multisyst\u00E9movou formou histiocyt\u00F3zy z Langerhansov\u00FDch bun\u011Bk (LCH), rezistentn\u00ED ke 2-chlorodeoxyadenosinu a \u010Dasn\u011B relabuj\u00EDc\u00ED po vysokod\u00E1vkovan\u00E9 chemoterapii ..." . "Brejcha, Martin" . "Moulis, Mojm\u00EDr" . "146806" . "Kodet, R." . "Zahradov\u00E1, Lenka" . "Koukalov\u00E1, R." . . . "\u0158eh\u00E1k, Zden\u011Bk" . . . "Krej\u010D\u00ED, Marta" . . "H\u00E1jek, Roman" . "Vnit\u0159n\u00ED l\u00E9ka\u0159stv\u00ED" . . "Szturz, Petr" . "RIV/00216224:14110/12:00059513!RIV13-MZ0-14110___" . "Lenalidomid indukoval l\u00E9\u010Debnou odpov\u011B\u010F u pacienta s agresivn\u00ED multisyst\u00E9movou formou histiocyt\u00F3zy z Langerhansov\u00FDch bun\u011Bk (LCH), rezistentn\u00ED ke 2-chlorodeoxyadenosinu a \u010Dasn\u011B relabuj\u00EDc\u00ED po vysokod\u00E1vkovan\u00E9 chemoterapii ..." . "Adamov\u00E1, Z." . . "Nebesk\u00FD, Tom\u00E1\u0161" . "CZ - \u010Cesk\u00E1 republika" . "Adult Langerhans cell histiocytosis (LCH) usually follows a positive course. Very rarely, LCH involves multiple systems (multiple organ LCH) and is difficult to manage either with the traditional first line treatment (vinblastine, mercaptopurine, prednisone or etoposide) or with 2-chlorodeoxyadenosine. Other treatment modalities have to be used in these patients. We describe a patient with LCH that caused generalized lymphadenopathy and infiltrated pulmonary parenchyma and the skin. The disease activity was always associated with the B symptoms (weight loss, subfebrile states, night sweats). Histological investigations repeatedly showed higher proliferation activity than what is usual in adult patients with LCH. Proliferation marker Ki-67 expression was up to 30% and there were 8\u201310 mitoses in the field of view of the microscope."@en . "[65418573E944]" . "Lenalidomid induced therapeutic response in a patient with agressive multisystemic Langerhans cell histiocytosis, resistant to 2-chlorodeoxyadenosine and early relapsing after high dose chemotherapy ..."@en .